Faculty Collaboration Database

Ingested (oral) IFN-alpha represses TNF-alpha mRNA in relapsing-remitting multiple sclerosis. J Interferon Cytokine Res 2006 Mar;26(3):150-5

Date

03/18/2006

Pubmed ID

16542137

DOI

10.1089/jir.2006.26.150

Scopus ID

2-s2.0-33645419764 (requires institutional sign-in at Scopus site)   10 Citations

Abstract

In a phase II trial in relapsing-remitting multiple sclerosis (RRMS), patients ingesting 10,000 IU, but not 30,000 IU, interferon-alpha (IFN-alpha) showed fewer gadolinium enhancements at months 5 and 6, along with decreased proinflammatory tumor necrosis factor-alpha (TNF-alpha) protein secretion. Therefore, we examined MxA mRNA induction and TNF-alpha mRNA repression after 100, 300, 1,000, 3,000, and 10,000 IU doses of ingested IFN-alpha in 24 RRMS patients to determine the optimal dose for future clinical trials in MS. Maximal TNF-alpha repression occurs at 100, 1,000, and 3,000 IU. These data provide new optimal doses for additional clinical studies using ingested IFN-alpha in MS.

Author List

Brod SA, Nguyen M, Hood Z, Shipley GL

MESH terms used to index this publication - Major topics in bold

Administration, Oral
Adolescent
Adult
Dose-Response Relationship, Drug
GTP-Binding Proteins
Humans
Interferon-alpha
Leukocytes, Mononuclear
Middle Aged
Multiple Sclerosis, Relapsing-Remitting
Myxovirus Resistance Proteins
RNA, Messenger
Reverse Transcriptase Polymerase Chain Reaction
Tumor Necrosis Factor-alpha